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Introduction
Prothrombin complex concentrates (PCCs) were origi-
nally developed as a source of factor IX for the treatment 
of patients with haemophilia B [1]. Subse  quently, PCCs 
were used in the treatment of bleeding in haemophilia 
patients with inhibitors [1]. Th  ese concen  trates have 
largely been superseded in this setting by high-purity, 
plasma-derived factor IX and, more recently, recom-
binant factor IX and bypassing agents such as activated 
PCC and recombinant activated factor VII.
Today, PCCs are mainly used for the emergency 
reversal of oral vitamin K antagonist (VKA) therapy [2,3], 
although in the USA they are only approved for haemo-
philia. Bleeding is the most frequent complication of oral 
anticoagulation, causing considerable morbidity and 
mortality [4]. Emergency reversal of anticoagulation is 
most commonly needed to control bleeding as quickly as 
possible. Th  e use of PCCs has also been proposed in 
severe liver disease and in perioperative and trauma-
related bleeding [5-8], although fewer studies have been 
performed in these settings than for anticoagulation 
reversal.
Most commercially available PCCs contain four 
vitamin K-dependent coagulation factors (II, VII, IX and 
X), although not all contain factor VII (Table 1). A recent 
study of PCC constituents found broad correlation with 
the products’ labelled values [9]. In most currently 
available PCCs, the factors are found in the inactivated 
form. In addition to the coagulation factors, many of 
today’s PCCs include one or more of the following 
coagulation inhibitors: heparin, antithrombin, protein C, 
protein S and protein Z.
In settings where rapid correction of coagulopathy is 
required, such as in cases of intracranial haemorrhage 
[10], PCCs may oﬀ  er some advantages over fresh frozen 
plasma (FFP), the traditionally established therapy. For 
reasons such as reduced volume, room-temperature 
storage and lack of requirement for blood type matching, 
the total time for administration is much reduced with 
PCCs compared with FFP. Furthermore, most currently 
available PCCs are subjected to at least one viral in  acti-
vation step (Table 1), which reduces the risk of pathogen 
transmission. Also, as PCCs are free of leukocytes and 
some are also nanoﬁ  ltrated, they are unlikely to provoke 
transfusion-related acute lung injury.
Historically, the major drawback of PCCs has been the 
risk of thrombotic complications [11]. Today’s PCCs 
diﬀ  er considerably from the preparations used to treat 
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© 2011 BioMed Central Ltdhaemophiliacs in the 1970s and 1980s, and in general the 
risk of thrombosis with PCCs appears to have been 
reduced. Nevertheless, accurate risk–beneﬁ  t assessments 
of PCC therapy are dependent on thorough under-
standing of the potential for thrombogenicity. Th  e aims 
of the present review are to provide a systematic overview 
of thrombotic complications reported with PCCs, to 
examine the possible pathogenesis of thrombotic events, 
and to discuss safety precautions and means to reduce 
thrombotic complications. Furthermore, the review 
performs a critical comparison of PCC with FFP.
Literature search strategy
We used the PUBMED database to search for publi-
cations with ‘complex concentrate(s)’ or ‘coagulation 
factor concentrate(s)’ as key words, plus additional terms 
including ‘anticoagulation reversal’ and ‘over-anticoagu-
la  tion’. Citations were selected from articles published in 
English between 1988 and 2010.
Thrombotic complications with PCCs
Th   rombotic complications associated with PCCs include 
venous thromboembolism, disseminated intravascular 
coagulation (DIC), microvascular thrombosis and 
myocardial infarction [1]. An overview of studies that 
have reported such complications is presented in Table 2. 
Th  e risk of thrombotic complications occurring with 
PCCs or other procoagulant haemostatic interventions 
must be considered in the context of any underlying 
disease and the patient’s clinical condition at the time of 
PCC administration [12].
Haemophilia
Prior to the introduction of high-purity, plasma-derived 
factor IX, haemophilia B patients were treated with 
PCCs. As haemophilia B patients are deﬁ  cient in factor 
IX only, administration of PCC will produce supra-
physiological levels of the other factors in the preparation – 
this, coupled with the need for repetitive dosing in 
haemophilia B, can increase patients’ risk of thrombosis. 
Since the introduction of PCCs for haemo  philia in the 
1960s, complications such as deep vein thrombosis, DIC 
and pulmonary embolism have been reported. In a 
survey of 150 physicians in several coun  tries, 72 
thrombotic complications occurring between 1987 and 
1990 were reported [11]. An increased risk of adverse 
eﬀ  ects was seen in patients with large muscle haema-
tomas, immobilisation and orthopaedic surgery. In these 
conditions, treatment involves administration of large, 
repeated doses of PCCs [11]. In the 1980s, several cases 
of acute myocardial infarction in young haemo  philiacs 
with inhibitors were reported; many of these patients had 
received large, repeated doses of PCCs [13].
Anticoagulation reversal
All patients receiving VKA therapy have underlying 
thrombotic risk factors, which may be unmasked when 
anticoagulation is reversed. A review of 14 studies each 
Table 1. Composition of PCCs in the World Federation of Hemophilia register of clotting factor concentrates
  International units relative to factor IX
    Factor Factor  Factor Factor    Additional
Brand name  Manufacturer  II  VII  IX  X  Viral inactivation  information
Bebulin VH  Baxter BioScience,   120  (13)  100  100  Vapour heat, 60°C for 10 hours at 190 mbar,  Heparin added
  Austria           then 80°C for 1 hour at 375 mbar
Beriplex P/N  CSL Behring,   128  68  100  152  Pasteurisation at 60°C for 10 hours, and   Protein C; 
  Germany       nanofi   ltration  antithrombin,  heparin 
           and  albumin  added
Cofact  Sanquin,   56-140  28-80  100  56-140  Solvent/detergent and 15 nm  Antithrombin added
  the  Netherlands       nanofi   ltration
KASKADIL  LFB, France  148  40  100  160  Solvent/detergent  Heparin added
Octaplex  Octapharma, Austria   44-152  36-96  100  50  Solvent/detergent and nanofi  ltration  Heparin added; low
  and  France           activated  factor  VII 
           content
Profi  lnine SD  Grifols, USA  148  (11)  100  64  Solvent/detergent  –
Prothrombinex VF  CSL Bioplasma,   100  (–)  100  100  Dry heat, 80°C for 72 hours and  –
  Australia       nanofi   ltration
Prothromplex T  Baxter BioScience,   100  85  100  100  Vapour heat, 60°C for 10 hours at 190 mbar,  Antithrombin and
  Austria           then 80°C for 1 hour at 375 mbar  heparin added
UMAN Complex D.I.  Kedrion, Italy  100  (–)  100  80  Solvent/detergent and dry heat, 100°C for   Antithrombin and
         30  minutes  heparin  added
Composition of prothrombin complex concentrates (PCCs) listed in the World Federation of Hemophilia register of clotting factor concentrates [54], excluding 
concentrates for national markets only or for which the concentrations of factors relative to factor IX were not available from the relevant product information sheets. 
Factor VII presented in parentheses for three-factor PCCs.
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Page 2 of 9involving at least 10 patients (a total of 460 patients) in 
which PCCs were administered for anticoagulation 
reversal revealed no evidence of DIC [14]. Th  ere were, 
however, seven thrombotic complications (that is, 1.5% of 
patients experienced a thrombotic event). Four of these, 
two deep vein thromboses and two non-ST elevation 
myocardial infarctions which were identiﬁ  ed in a retro-
spective review of 58 patients, were not attributed to 
PCC therapy [15]. Two throm  botic strokes occurred in 
patients with extensive co-morbidities [16]. Th  e ﬁ  rst 
patient, a 75-year-old male, suﬀ  ered from multi-infarct 
brain damage, longstanding hypertension, atrial ﬁ  bril  la-
tion and vascular disease of the legs. Th  e other patient 
was an 86-year-old female with atrial ﬁ  brillation and a 
large haematoma in the left leg. Finally, a patient with 
peripheral vascular disease, sepsis and renal and cardiac 
failure died of a thrombotic stroke 48 hours after PCC 
treatment, following leg ampu  tation [17].
Th  ree further thrombotic complications associated 
with PCC use have been identiﬁ  ed in articles published 
since Leissinger and colleagues’ review [14]. A study of 
PCC use in 43 patients requiring emergency reversal of 
VKA therapy was published more recently [18]. One 
serious adverse event, suspected pulmonary embolism 
leading to the death of a patient, was considered possibly 
related to study treatment. Th   is patient had an underlying 
risk of thrombosis relating to metastatic gastrointestinal 
cancer and atrial ﬁ  brillation. In a recent case report, a 
patient receiving PCC for anticoagulant reversal suﬀ  ered 
a fatal myocardial infarction [19]. Myocardial infarction 
is a fre  quent perioperative complication in the absence of 
PCC treatment and no deﬁ   nite causal link with PCC 
adminis  tration could be established in this case. 
Furthermore, the patient may have had DIC related to 
abdominal sepsis. A second case report, published by 
Warren and Simon, involved a patient who received 
treatment with PCC and subsequently suﬀ  ered massive, 
fatal intracardial throm  bosis [20]. Although the authors 
suggest this may have been a complication of PCC 
treatment, there were several important underlying risk 
factors. Th   e patient had a history of ischaemic stroke and 
deep venous thrombosis. Th  e International Normalised 
Table 2. Studies reporting thrombogenic complications associated with the use of PCCs
       Number  of
   PCC Number  of  thrombotic   
Publication  Study type  indication  patients  complications  Nature of complications  Notes
Lusher [11]  Physician survey   Haemophilia  Not available  72 (reported  Various (for example, deep  Increased risk among patients
  and registry    (150 physicians   over a  venous thrombosis of the  receiving large, repeated
      surveyed)  4-year period)  leg, pulmonary embolus, DIC)  doses of PCC
Lankiewicz and  Retrospective  Warfarin reversal  58  4  Deep vein thrombosis (n = 2),  Thrombotic complications
colleagues [15]  review        non-ST elevation myocardial   were not attributable to PCC
         infarction  (n = 2)  therapy
van Aart and   Prospective,   Oral anticoagulation  93  2  Thrombotic stroke (n = 2)  Both patients were elderly and
colleagues [16]  randomised   reversal        had atrial fi  brillation; one had
  controlled trial  (acenocoumarol or         vascular disease and the other
    phenprocoumon)        had a large haematoma
Preston and   Prospective,   Warfarin reversal  42  1  Thrombotic stroke  Stroke occurred following leg
colleagues [17]  uncontrolled          amputation, 48 hours after 
  trial          PCC treatment. Patient had 
            peripheral vascular disease
Pabinger-  Prospective,   Oral anticoagulation  43  1  Suspected pulmonary  Patient had risk of thrombosis
Fasching and   uncontrolled  reversal (vitamin K      embolism (fatal)  due to metastatic
colleagues   trial  antagonists)        gastrointestinal cancer and 
[18,55]          atrial  fi   brillation
Bagot and   Case report  Warfarin reversal  1  1  Myocardial infarction (fatal)  No defi  nite causal link with 
colleagues [19]            PCC administration; patient 
            may have had DIC related to 
           abdominal  sepsis
Warren and   Case report  Warfarin reversal  1  1  Intracardial thrombosis (fatal)  Patient had a history of 
Simon [20]            ischaemic stroke and deep 
            venous thrombosis; general 
            disturbance of coagulation
Kohler and   Case reports  Perioperative setting,  5  5  Thrombotic events (fatal)  All patients received an old 
colleagues [22]  (n = 5)  acquired defi  ciencies         PCC that was withdrawn in
    of coagulation factors         1994; all patients had 
           underlying  diseases 
            predisposing them to 
            thrombosis or DIC
DIC, disseminated intravascular coagulation; PCC, prothrombin complex concentrate.
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plastin time was elongated, suggesting very low levels of 
prothrombin, factor VII  and protein C; levels of liver 
enzymes were also high. Th  ese factors indicate general 
disturbance of coagu  lation independent of PCC adminis-
tration. Furthermore, serum potassium was at a level high 
enough to potentially cause cardiac arrest, and the patient’s 
creatinine level (5.2 mg/dl) indicates renal failure.
In all of these cases, therefore, the patients receiving 
PCCs had increased risk of thrombosis due to medical 
history or current illness. As this reﬂ   ects the usual 
context of PCC administration, a small number of 
compli  cations may be expected. Th   e possibility that PCC 
administration has some inﬂ  uence over the risk cannot 
be excluded. In most recent cases in the literature, 
however, it seems unlikely that PCC alone was the cause.
Perioperative and trauma-related bleeding
During the past decade, there have been several reports 
of PCC therapy for critical bleeding. Th  e aim of this 
approach is to correct critically reduced thrombin 
generation, resulting from major blood loss, consumption 
of coagulation factors and volume administration (this 
excludes patients requiring anticoagulation reversal or 
with a procoagulant status and prophylactic use of PCCs). 
Although there have been few authoritative studies of 
PCCs in this setting, the clinical practice has been used in 
European countries such as Austria, Germany and Swit-
zer  land in cases with increased bleeding and prolonged 
initiation of coagulation as measured by viscoelastic 
techniques [21]. Recently published Austrian expert 
opinion consensus recommendations advocate adminis-
tration of PCC (20 to 30 IU/kg bodyweight) in the case of 
persistent bleeding and prolonged clotting time [6]. 
Adequate substitution of ﬁ   brinogen was also recom-
mended, prior to administration of PCC.
Regarding the possible complications associated with 
accelerating thrombin generation by administration of 
PCC in the perioperative setting, a cluster of ﬁ  ve fatal 
PCC-related thrombotic events  in German patients 
under  going surgery was reported in the 1990s [22]. None 
of these cases may be considered classical perioperative 
PCC use: two patients required anticoagulation reversal, 
two patients had procoagulant states (including sepsis, 
DIC or high levels of platelets and ﬁ  brinogen), and one 
patient received PCC prophylactically (that is, without 
clinical signs of bleeding). All ﬁ  ve patients were treated 
with an old PCC that was withdrawn from the market in 
1994 as a result of three of the fatalities [22]. Compared 
with other PCCs available at the time, the withdrawn 
product had high levels of factors II and X and activated 
factor VII, low levels of protein S, and no free 
antithrombin activity, although heparin levels were 
relatively high [22,23]. Co-administration of aprotinin 
was also identi  ﬁ  ed as playing a possible role in three of 
the cases [22]. More recently, there have been no reports 
of thrombotic complications with PCCs in the treatment 
of perioperative or trauma-related bleeding, although 
only a few studies have been published in these settings 
[8,24,25].
PCCs and thrombotic risk: pathogenesis
Th   e potential causes of thrombogenic complications after 
PCC administration remain a subject for debate. Early 
studies in animal models implicated activated factor IX or 
the presence of procoagulant phospholipids as poten  tial 
thrombogenic determinants in PCCs [26,27]. A reduc  tion 
in thromboembolic complications among haemo  philia B 
patients was observed when highly-puriﬁ   ed factor IX 
began to replace PCCs. However, direct measure  ment of 
activated factor IX revealed that there tended to be higher 
levels in highly-puriﬁ   ed factor IX preparations than in 
PCCs [28], suggesting that levels of activated factor IX do 
not correlate with thrombogenicity.
An in vitro model of thrombogenicity has been used 
recently to systematically examine which components of 
PCCs contribute to thrombogenicity [29]. Zymogen 
overload, of prothrombin in particular, was implicated in 
this study as the main mechanism for the thrombogenic 
potential of PCCs. Other studies have also cited pro-
thrombin as the major determinant of excessive thrombin 
generation in an activated PCC preparation [30].
Th   e need for balance between procoagulants and anti-
coagulants was suggested by a recent in vitro study of 
thrombin generation in blood from patients with liver 
cirrhosis [31]. Th  e authors suggest that haemostasis is 
preserved in these patients because the reduction of 
procoagulants (factor II) is balanced by reduced levels of 
the coagulation inhibitor protein C.
Two studies, using diﬀ   erent methodologies, have 
shown that increased levels of factors VII, IX and X did 
not inﬂ  uence total thrombin generation [32,33]. In con-
trast, there is a linear relationship between increasing 
levels of factor II and increased thrombin generation 
[32,33]. Finally, a recently published study has shown 
that, following activation with a high concentration of 
tissue factor, prothrombin is amongst the main deter  mi-
nants of total thrombin generation [34]. Th  e available 
evidence therefore indicates that accumulation of factor 
II could be the primary determinant of thrombotic risk 
associated with frequent doses of PCC. Th   e half-lives of 
the coagulation factors diﬀ  er considerably, with factors II 
and X having the longest half-lives of the factors 
administered in PCC (60 and 30 hours, respectively, 
compared with 6 hours for factor VII and 20 hours for 
factor IX) [35]. As a consequence, repeated dosing will 
lead to an accumulation of factors II and X as illustrated 
in Figure 1.
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component(s) of PCCs is the leading cause of thrombo-
genicity, but there is accumulating evidence for the 
impor  tance of factor II and the balance between this 
coagulation factor and coagulation inhibitors.
Diff  erences between today’s PCCs and older 
products
Today’s PCCs have improved safety compared with those 
used in the 1970s and 1980s [12]. Th  is improvement is 
probably related to the inclusion of coagulation inhibitors 
such as heparin, antithrombin, protein C, protein S and 
protein Z. Th  ese constituents may be speculated to 
provide some balance to the eﬀ  ects of the coagulation 
factors, the aims being to avoid excessive increase in 
thrombin generation and to reduce thrombotic risk. Th  e 
inclusion of coagulation inhibitors is consistent with 
recommendations to administer early PCCs together 
with heparin and antithrombin [11].
Th  e  eﬀ  ects of one currently available PCC (Beriplex P/N; 
CSL Behring, Marburg, Germany) have been studied in 
healthy volunteers (n = 15) [36]. Considerable increases 
in coagulation factor levels were observed, and these 
were accompanied by increases in plasma concentrations 
of proteins C and S. Importantly, there was no clinical 
evidence of thrombosis, and no increase in the 
thrombogenicity marker D-dimer [36].
In a recent study, the biochemical composition of seven 
commercially available PCCs was measured. With one 
exception – Uman Complex (Kedrion, Castelvecchio 
Pascoli, Italy), which contained negligible factor VII – 
coagulation factor levels were broadly similar in all seven 
products, and all tested negative for activated coagulation 
factors [9]. Th  ere were, however, some diﬀ  erences  in 
coagu  lation inhibitor levels (Figure 2), resulting in diﬀ  er  ent 
thrombin inhibitory capacities. Th  ere were also con-
siderable purity diﬀ   er  ences between the products. It is 
noteworthy that all of the PCCs contained considerable 
concentrations of pro  thrombin (factor II), and that S-TIM 
4 or Prothromplex (Baxter, Vienna, Austria) had a higher 
factor II:factor IX ratio than the other products [9].
Pharmacovigilance data for some of the currently 
available PCCs (Table 3) demonstrate that, although 
millions of units have been administered to thousands of 
patients, there have been no proven cases of infection 
transmission, heparin-induced thrombocytopaenia or 
thromboembolism.
One may question how the safety proﬁ   le of today’s 
three-factor PCCs compares with that of the four-factor 
products. Unfortunately no comparator trials have been 
performed, so there are no deﬁ  nitive answers. Given the 
apparent importance of factor II in thrombotic risk, and 
the fact that the key diﬀ  erence between the two types of 
PCC is the presence or absence of factor VII, no major 
inherent diﬀ  erences may be expected. Th  ree-factor  PCCs 
have been reported as suboptimal for warfarin reversal, 
owing to the absence of factor VII [37]. Th   us. it has been 
recommended that four-factor PCCs are probably 
preferable to three-factor PCCs or FFP, for acute reversal 
of oral VKAs [38].
Comparing PCCs with human plasma
Th  e primary alternative to PCCs – particularly for 
anticoagulant reversal, but also for treatment of acquired 
coagulopathy in the perioperative setting – is human 
plasma. Th  rombotic complications with human plasma 
Figure 1. Coagulation factors accumulate diff  erently when a prothrombin complex concentrate is administered repeatedly. Illustration of 
how coagulation factors accumulate diff  erently when a prothrombin complex concentrate (PCC) is administered repeatedly due to their diff  erent 
half-lives. The example shows the theoretical accumulation of factors in plasma sampled immediately after dosing when 40 units/kg four-factor 
PCC is given every 12 hours to a 70 kg patient.
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PCCs. However, there are major drawbacks with human 
plasma versus PCCs. Firstly, a considerably longer time is 
taken to reach haemostasis with human plasma. Before it 
can be administered, compatibility testing is required and 
the human plasma must be thawed and warmed. Th  e  low 
concentration of coagulation factors in normal human 
plasma means that a large volume may be required to 
deliver enough of the factors to achieve eﬀ  ective 
haemostasis. As well as the risk of volume overload, this 
results in an extended administration time. Hence, the 
time taken for preparation and administration of human 
plasma is typically 1 or 2 hours. In contrast, PCCs can be 
administered immediately and a lower volume is required; 
an important consideration when the rapid reversal of 
anticoagulant therapy may be life-saving.
Human plasma transfusion is associated with other 
potential adverse reactions, including transfusion-related 
acute lung injury and allergic reaction [39]. FFP is also 
associated with a risk of allergic reactions, such as skin 
rash, pruritus, urticaria, bronchospasm, angioedema and 
anaphylactic shock [40]. Studies have shown that infusion 
of FFP is associated with increased risk and frequency of 
hospital-acquired infections [41], and that there is a small 
potential risk of disease transmission with human plasma 
[5]. In contrast, PCC manufacture includes at least one 
step of viral reduction or elimination, which minimises 
the risk of transmitting infectious agents.
It is discouraging, faced with the potential side-eﬀ  ects 
of FFP, that available data on the eﬃ   cacy of FFP are scarce 
[42,43]. Several studies comparing the eﬃ   cacy of PCCs 
with human plasma for emergency oral anticoagulant 
Figure 2. Coagulation inhibitor levels of diff  erent prothrombin complex concentrates. Protein C, protein S and protein Z contents of diff  erent 
prothrombin complex concentrates (PCCs) [9].
Table 3. Pharmacovigilance data for some of the commercially available PCCs
       Number  of  Number  of 
    Amount  Estimated  cases of  Number of  cases of 
Brand name  Dates of  produced  number of  proven infection  cases of  proven 
(manufacturer)  survey  to date  applications  transmission  HIT type II  thromboembolism
Beriplex P/N   1996 to 2004  >400 million  >200,000   0  0  0 (two cases were reported
(CSL Behring,     units  (average dose      but PCC not established as 
Germany)     2,000  units)     the  cause)
Cofact   1997 to 2006  ~97 million   ~64,000 to 82,500   0  0  0
(Sanquin,     units  (average dose
The Netherlands)      20 to 50 ml)
Uman   2005 to 2007  ~31.5 million   ~16,000   0  0  0
Complex D.I.     units  (average dose
(Kedrion, Italy)      2,000 units)
Pharmacovigilance data for some of the commercially available prothrombin complex concentrates (PCCs) listed in the World Federation of Hemophilia register of 
clotting factor concentrates, excluding those for national markets only [54]. HIT, heparin-induced thrombocytopaenia.
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and more rapid correction of coagulopathy [44-47]. 
Th  ese  ﬁ  ndings, together with the improved safety proﬁ  le 
of today’s PCCs, suggest that PCCs should be considered 
preferable to FFP for emergency oral anticoagulant 
reversal. Th  is is reﬂ   ected in the latest British and 
American guidelines on the reversal of anticoagulation as 
well as other review articles [2,3,14,38].
Possible means of reducing thrombotic risk
As PCCs were originally designed for the treatment of 
haemophilia B, their labelling, and thus dosage, is based 
on the concentration of factor IX. When PCCs are used 
for VKA reversal, it is important to recognise that 
warfarin reduces the levels of the vitamin K-dependent 
coagulation factors to varying degrees, with factor IX 
remaining at 40 to 50% of normal levels, factor VII at 
around 30% of normal, prothrombin at 20% of normal 
and factor X is usually lowest at around 10% of normal 
[48]. As a result, it is diﬃ   cult to deﬁ  ne the optimal ratio 
of factors in a PCC. Care should be taken, however, to 
avoid excessive substitution with prothrombin, particu-
larly during repetitive administration of PCCs when 
prothrombin levels can accumulate because of its long 
half-life. Co-administration of vitamin K is recommended 
when PCCs are used for anticoagulation reversal [2]. 
Vitamin K has a slow onset of action, and the reason for 
its use is to facilitate hepatic production of coagulation 
factors after the constituents of the PCC infusion have 
been metabolised. By reducing the need for repeat 
administration of PCC, co-adminis  tration of vitamin K is 
one way of reducing thrombotic risk.
Although the primary purpose of PCCs is the 
restoration of coagulation factors, it is also important to 
consider levels of coagulation inhibitors. VKA therapy 
reduces levels of protein C, protein S and protein Z as 
well as the coagulation factors, and the concentration of 
circulating coagulation inhibitors will be reduced in 
dilutional coagulopathy. Furthermore, chronic liver 
disease – which was identiﬁ  ed as a risk factor for throm-
botic complications in haemophilia patients treated with 
earlier formulations of PCCs [12] – frequently causes a 
reduction in the production of antithrombin as well as 
coagulation factors [49]. To avoid thrombotic compli-
cations, monitoring of antithrombin activity and co-
administration of antithrombin concentrate should be 
considered when administering PCCs to patients with 
severe liver disease [5]. Patients with low levels of 
endogenous anti  thrombin are likely to be at increased 
risk of thrombosis. Th   ere is, therefore, a strong rationale 
for the inclusion of coagulation inhibitors such as protein 
C, protein S and protein Z or antithrombin in PCCs [50].
Accurate bedside monitoring of a patient’s coagulation 
status may provide a means for reducing thrombotic risk. 
Conventional coagulation tests such as the prothrombin 
time are not aﬀ  ected by levels of coagulation inhibitors 
such as protein C; the International Normalised Ratio 
may therefore not be a true reﬂ  ection of the haemostatic 
state of a patient [31]. During volume replacement of 
blood loss, particularly with colloids, conventional 
prothrombin time and activated partial thromboplastin 
time assays may suggest critical reduction in coagulation 
factors, whereas the coagulation time measured in whole 
blood using thrombo  elasto  graphy may remain within the 
normal range [51]. Th  eoretically, thrombin generation 
measurement should be preferable for guiding PCC 
administration and monitoring its eﬃ   cacy. Th  is  analysis 
is not yet routine in all laboratories, but thromboelasto-
graphy provides a surrogate estimate of thrombin genera-
tion in whole blood [52,53].
Ultimately, it is incumbent upon physicians to seek 
suﬃ   cient restoration of thrombin generation to achieve 
haemostasis. Normalisation may not be needed and may 
unmask an underlying predisposition of thrombo  embo-
lism. An excessive increase in thrombin generation 
should thus be avoided. Caution must be exercised, and 
PCCs are generally not recommended for use in patients 
at very high risk of thrombosis, such as those with clinical 
or laboratory evidence of overt DIC.
Conclusions
Th  e paradox remains that PCCs are eﬀ  ective because 
they increase the body’s ability to generate thrombin, 
while the total thrombin generation constitutes the 
primary safety concern with their use. Th  e overall 
capacity to produce thrombin seems to be primarily 
associated with prothrombin levels. Th   e use of PCCs in 
patients predisposed to thrombogenic complications 
makes it diﬃ   cult to determine whether thrombogenic 
events are attributable to or merely coincidental with 
PCC treatment. Th  rombotic risk in patients without 
underlying risk appears to be fairly low with today’s 
PCCs. Changes to the production of PCCs, designed to 
address the possible causes of thrombogenic compli-
cations, have contributed to their improved safety. 
Th  ese changes include the avoidance of activated 
factors, greater purity and a well-balanced content of 
clotting factors and inhibitors. However, additional 
factors that may contribute to thrombotic complications 
associated with PCC use remain to be elucidated. Th  e 
putative beneﬁ  t of combined administration of PCCs 
with anti  thrombin in high-risk patients such as those 
with liver insuﬃ     ciency or on VKA therapy is as yet 
unconﬁ  rmed.
In patients with emergency bleeding, the risk of a 
thrombotic complication due to treatment with PCCs 
should be weighed against the need for rapid and 
eﬀ  ective correction of coagulopathy.
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